Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
An Open-Label, Phase 1, Two-Way, Crossover Study of the Effect of Food on the Pharmacokinetics of TAK-659 in Patients With Advanced Solid Tumor and/or Lymphoma Malignancies
Status: Enrolling
Updated:  3/26/2018
Yale Cancer Center
mi
from
New Haven, CT
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
An Open-Label, Phase 1, Two-Way, Crossover Study of the Effect of Food on the Pharmacokinetics of TAK-659 in Patients With Advanced Solid Tumor and/or Lymphoma Malignancies
Status: Enrolling
Updated: 3/26/2018
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
An Open-Label, Phase 1, Two-Way, Crossover Study of the Effect of Food on the Pharmacokinetics of TAK-659 in Patients With Advanced Solid Tumor and/or Lymphoma Malignancies
Status: Enrolling
Updated:  3/26/2018
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
An Open-Label, Phase 1, Two-Way, Crossover Study of the Effect of Food on the Pharmacokinetics of TAK-659 in Patients With Advanced Solid Tumor and/or Lymphoma Malignancies
Status: Enrolling
Updated: 3/26/2018
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
An Open-Label, Phase 1, Two-Way, Crossover Study of the Effect of Food on the Pharmacokinetics of TAK-659 in Patients With Advanced Solid Tumor and/or Lymphoma Malignancies
Status: Enrolling
Updated:  3/26/2018
Montefiore Medical Center
mi
from
Bronx, NY
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
An Open-Label, Phase 1, Two-Way, Crossover Study of the Effect of Food on the Pharmacokinetics of TAK-659 in Patients With Advanced Solid Tumor and/or Lymphoma Malignancies
Status: Enrolling
Updated: 3/26/2018
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma
A Phase II Study of Brentuximab Vedotin as Salvage Therapy for Hodgkin Lymphoma Prior to Autologous Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  3/28/2018
City of Hope Medical Center
mi
from
Duarte, CA
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma
A Phase II Study of Brentuximab Vedotin as Salvage Therapy for Hodgkin Lymphoma Prior to Autologous Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 3/28/2018
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma
A Phase II Study of Brentuximab Vedotin as Salvage Therapy for Hodgkin Lymphoma Prior to Autologous Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  3/28/2018
Weill Medical College of Cornell University
mi
from
New York, NY
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma
A Phase II Study of Brentuximab Vedotin as Salvage Therapy for Hodgkin Lymphoma Prior to Autologous Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 3/28/2018
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
A Dose-Ranging Study of Bendamustine and Rituximab in Chronic Lymphocytic Leukemia (CLL) Patients With Comorbidities and/or Renal Dysfunction
Status: Enrolling
Updated:  3/28/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
A Dose-Ranging Study of Bendamustine and Rituximab in Chronic Lymphocytic Leukemia (CLL) Patients With Comorbidities and/or Renal Dysfunction
Status: Enrolling
Updated: 3/28/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
A Dose-Ranging Study of Bendamustine and Rituximab in Chronic Lymphocytic Leukemia (CLL) Patients With Comorbidities and/or Renal Dysfunction
Status: Enrolling
Updated:  3/28/2018
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
mi
from
Lebanon, NH
BR in Patients With CLL With Comorbidities and/or Renal Dysfunction
A Dose-Ranging Study of Bendamustine and Rituximab in Chronic Lymphocytic Leukemia (CLL) Patients With Comorbidities and/or Renal Dysfunction
Status: Enrolling
Updated: 3/28/2018
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Rituximab Plus CHOP Given Every Two Weeks With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  3/30/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Rituximab Plus CHOP Given Every Two Weeks With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 3/30/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  3/30/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 3/30/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase II Trial of Low Toxicity GVHD Prevention and Enhanced Immune Recovery With Tacrolimus, Bortezomib and Thymoglobulin® TBT
Status: Enrolling
Updated:  3/30/2018
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase II Trial of Low Toxicity GVHD Prevention and Enhanced Immune Recovery With Tacrolimus, Bortezomib and Thymoglobulin® TBT
Status: Enrolling
Updated: 3/30/2018
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase I Trial Of Intravenous Bispecific Antibody (4G7XH22) In Patients With Refractory Or Relapsed Non-Hodgkin's Lymphoma Or Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  4/2/2018
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase I Trial Of Intravenous Bispecific Antibody (4G7XH22) In Patients With Refractory Or Relapsed Non-Hodgkin's Lymphoma Or Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 4/2/2018
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
A Phase Ib Study of The Safety and Pharmacology of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  4/3/2018
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
A Phase Ib Study of The Safety and Pharmacology of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 4/3/2018
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
A Phase Ib Study of The Safety and Pharmacology of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  4/3/2018
Tennessee Oncology, PLLC
mi
from
Nashville, TN
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
A Phase Ib Study of The Safety and Pharmacology of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 4/3/2018
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
A Phase II Clinical Trial of Sapacitabine, Cyclophosphamide, and Rituximab (SCR) for Relapsed Patients With Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) and Deletion 11q22-23 by FISH
Status: Enrolling
Updated:  4/5/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
A Phase II Clinical Trial of Sapacitabine, Cyclophosphamide, and Rituximab (SCR) for Relapsed Patients With Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) and Deletion 11q22-23 by FISH
Status: Enrolling
Updated: 4/5/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes
Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes
Status: Enrolling
Updated:  4/5/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes
Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes
Status: Enrolling
Updated: 4/5/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
An Open-Label Phase II Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Status: Enrolling
Updated:  4/5/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
An Open-Label Phase II Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Status: Enrolling
Updated: 4/5/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Status: Enrolling
Updated:  4/6/2018
Columbia University Medical Center
mi
from
New York, NY
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Status: Enrolling
Updated: 4/6/2018
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Status: Enrolling
Updated:  4/6/2018
British Columbia Cancer Agency
mi
from
Vancouver,
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Status: Enrolling
Updated: 4/6/2018
British Columbia Cancer Agency
mi
from
Vancouver,
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Moore UCSD Cancer Center
mi
from
La Jolla, CA
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Moore UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
UCLA Division of Hematology-Oncology
mi
from
Los Angeles, CA
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
UCLA Division of Hematology-Oncology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
University of California at San Francisco
mi
from
San Francisco, CA
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Rocky Mountain Cancer Centers - Aurora
mi
from
Aurora, CO
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Rocky Mountain Cancer Centers - Aurora
mi
from
Aurora, CO
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Yale University
mi
from
New Haven, CT
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Georgetown University IRB
mi
from
Washington,
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Georgetown University IRB
mi
from
Washington,
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
MedStar Washington Hospital Center
mi
from
Washington,
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Cancer Centers of Florida
mi
from
Orlando, FL
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Cancer Centers of Florida
mi
from
Orlando, FL
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Augusta Oncology Associates
mi
from
Augusta, GA
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Augusta Oncology Associates
mi
from
Augusta, GA
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Central Georgia Cancer Care
mi
from
Macon, GA
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Central Georgia Cancer Care
mi
from
Macon, GA
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Cancer Care & Hematology Specialists of Chicagoland, PC
mi
from
Arlington Heights, IL
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Cancer Care & Hematology Specialists of Chicagoland, PC
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Hematology Oncology Assoc. of IL/Orchard Research LLC
mi
from
Chicago, IL
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Hematology Oncology Assoc. of IL/Orchard Research LLC
mi
from
Chicago, IL
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Rush University Medical Center
mi
from
Chicago, IL
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Consultants in Blood Disorders and Cancer
mi
from
Louisville, KY
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Consultants in Blood Disorders and Cancer
mi
from
Louisville, KY
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
St. Agnes - Medical Center
mi
from
Baltimore, MD
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
St. Agnes - Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Center for Cancer Research/CAMC
mi
from
Bethesda, MD
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Center for Cancer Research/CAMC
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Tufts Medical Center
mi
from
Boston, MA
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Henry Ford Hospital
mi
from
Detroit, MI
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Minnesota Oncology Hematology, P.A.
mi
from
Burnsville, MN
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Minnesota Oncology Hematology, P.A.
mi
from
Burnsville, MN
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Nebraska Cancer Specialists
mi
from
Omaha, NE
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Nebraska Cancer Specialists
mi
from
Omaha, NE
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Hackensack University Medical Center
mi
from
Hackensack, NJ
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Weill-Cornell Medical College
mi
from
New York, NY
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Columbia University Medical Center
mi
from
New York, NY
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Taussig Cancer Center, Cleveland Clinic Foundation
mi
from
Cleveland, OH
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Taussig Cancer Center, Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Accelerated Community Oncology Research Network Inc (ACORN)
mi
from
Memphis, TN
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Accelerated Community Oncology Research Network Inc (ACORN)
mi
from
Memphis, TN
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Mamie McFadden Ward Center
mi
from
Beaumont, TX
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Mamie McFadden Ward Center
mi
from
Beaumont, TX
Click here to add this to my saved trials
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated:  4/6/2018
Methodist Charlton Cancer Ctr.
mi
from
Dallas, TX
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
A Phase II, Multicenter, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive Or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy (GPI-06-0002)
Status: Enrolling
Updated: 4/6/2018
Methodist Charlton Cancer Ctr.
mi
from
Dallas, TX
Click here to add this to my saved trials